Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Marketing Home Genomics Tests Should Be Undertaken with Caution

By Labmedica staff writers
Posted on 27 Mar 2008
More than two-dozen companies have been marketing a range of genetic tests directly to consumers concerned about genetic conditions. More...
These conditions include those related to risks for disease, other genetic traits, and ancestry. Some of these companies have marketed "whole genome scans,” which provide assessments of risk for various health conditions ranging from the type of earwax an individual forms to a risk for disease, including cancer, diabetes, and blindness.

According to Dr. Kenneth Offit, M.D., M.P.H., chief of the Clinical Genetics Service at Memorial Sloan-Kettering Cancer Center (MSKCC; New York, NY, USA), marketing of "at home” genomic tests for disease risk may be premature. "Health professionals are now faced with the prospect of their patients coming to the office, a DNA profile in hand, asking for preventative management tailored to their specific disease risks,” Dr. Offit wrote in the March 19, 2008 special genomics issue of the Journal of the American Medical Association (JAMA).

Dr Offit is concerned about the scientific accuracy of some of these tests, because "they have not yet been validated in forward looking [prospective] clinical studies.” In addition, he wrote, the laboratory accuracy of these tests may vary. A second concern voiced in the commentary is the "direct to consumer” aspect of the marketing of these tests, which excludes guidance from healthcare professionals.

The JAMA article reminds readers that certain state health departments, including New York's, have indicated that genetic testing for disease risk must be requested by a licensed healthcare professional and must be performed in an approved clinical laboratory.

As one of the leaders of the clinical introduction of genetic testing for breast and colon cancer over the past decade, Dr. Offit is in favor of the cautious introduction of new "whole genome” testing, preferably in the setting of ongoing clinical trials. "Those of us in the field of genetic testing for cancer risk proceeded cautiously…The same approach should be followed for genomic testing for other disease risks” he said. "Not doing so runs the risk of dangerously reassuring some and needlessly worrying the already worried [as] well.”


Related Links:
Memorial Sloan-Kettering Cancer Center

Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.